Biotech company Regeneron and pharmaceutical giant Roche are joining together to increase capacity of Regeneron’s coronavirus antibody therapy.

The collaboration will allow Regeneron to increase its supply of the antibody therapy by at least three and a half times, the company said. The biotech company’s two-antibody combination REGN-COV2, is currently in late-stage clinical trials for the treatment and prevention of COVID-19.

Regeneron, an American company, will distribute the therapy in the U.S. and Roche, a Swiss company, will be responsible for distribution outside the U.S. once it is approved for those markets, officials said. Both companies will manufacture the antibody therapy, which was created by Regeneron, and both companies will fund and run the ongoing Phase 3 trial and Phase 1 safety studies.

The investigational antiviral antibody combination is a treatment option for people already experiencing symptoms of COVID-19 and “has the potential to prevent infection in people exposed to the virus, thus slowing the spread of the global pandemic,” according to the statement.

Bill Anderson, CEO of Roche, said in a statement that the company “has progressed the REGN-COV2 research and development program at record speed and worked tirelessly to maximize our in-house manufacturing capacity.”

REGN-COV2 is a double antibody therapy. Regeneron scientists sorted through thousands of human antibodies, including from people who recovered from COVID-19, to choose ones that fought the virus most effectively. Scientists chose two virus-neutralizing antibodies, scaled them up and put them into a medication in hopes that it could treat virus symptoms and possibly be used as a preventative measure.